Press Releases

Aug 5, 2026

Jordan Park

Press Releases

Origin Agritech Secures Exclusive Nationwide Rights to Zhongdan 6202, the Flagship Machine-Harvest Corn Hybrid Developed Under China's National 14th Five-Year Plan Breeding Program

Origin Agritech Ltd. (NASDAQ: SEED) has obtained exclusive commercial rights to Zhongdan 6202, a top-tier early-maturing corn hybrid developed under China's 14th Five-Year Plan. This variety addresses critical needs in the northeast Chinese corn market by enabling mechanized harvest with high yields, disease resistance, and cold tolerance. Origin p…

SEED

Aug 5, 2026

Derek Hwang

Press Releases

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering Corporation reported strong second quarter 2026 results highlighted by promising Phase 2a data showing a median overall survival of 17.3 months for pancreatic cancer patients treated with atebimetinib combined with chemotherapy. The company is progressing with its Phase 3 MAPKeeper 301 trial, dosing patients across over 30 locations. Ad…

IMRX

Aug 5, 2026

Priya Menon

Press Releases

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on rare skin diseases and vascular malformations, announced that its CEO Wes Kaupinen will participate in a fireside chat at the upcoming Canaccord Genuity Growth Conference. The company highlighted its pipeline, including its lead product candidate QTORIN™ 3.9% rapamycin gel…

PVLA

Aug 5, 2026

Hana Yamamoto

Press Releases

Mobilicom Secures Design Win and Initial Order with Tier-1 Israeli Defense Customer for New Loitering Munitions Platform

Mobilicom Limited announced a significant design win and initial order with a leading Tier-1 Israeli defense company to provide its cutting-edge SkyHopper MultiBand and Tactical solutions for a next-generation loitering munition platform. The selection follows successful field tests demonstrating superior connectivity and electronic warfare resista…

MOB

Aug 5, 2026

Marcus Reed

Press Releases

TransUnion Research Reveals Growing AI Confidence-Readiness Paradox Among Marketers

TransUnion's recent research highlights a confidence-readiness paradox among marketers investing in AI: while the majority are confident AI will transform marketing, many lack the foundational people, data, and process capabilities to fully realize AI's potential beyond efficiency gains. The study emphasizes data fragmentation as a key barrier affe…

TRU

Aug 5, 2026

Leila Farooq

Press Releases

Vishay Intertechnology Reports Second Quarter 2026 Results

Vishay Intertechnology, a leading manufacturer of discrete semiconductors and passive components, announced its Q2 2026 financial results showing a sequential revenue growth of 9.5% to $918.6 million (adjusted), surpassing the high end of guidance. The company reported a 23.3% GAAP gross margin and a diluted EPS of $0.19. Vishay's book-to-bill rati…

VSH

Aug 5, 2026

Priya Menon

Press Releases

Gilat Reports Second Quarter 2026 Results

Gilat Satellite Networks Ltd. reported robust second quarter 2026 financial results with revenues increasing 17% to $122.7 million and adjusted EBITDA growing 31% to $15.4 million. The company reiterated its 2026 financial guidance projecting continued revenue and EBITDA growth. Progress on the acquisition of Comtech's Satellite & Space Communicati…

GILT

Aug 5, 2026

Caleb Monroe

Press Releases

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical reported its Q2 2026 financial results, showing a slight revenue decrease compared to prior year periods. The company added multiple new late-stage programs to its pipeline, emphasized ongoing cost reduction and productivity improvements, and reaffirmed full-year 2026 revenue and Adjusted EBITDA guidance. Despite current losses,…

LFCR

Aug 5, 2026

Leila Farooq

Press Releases

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Fennec Pharmaceuticals, a specialty pharmaceutical company focused on reducing ototoxicity in cancer patients treated with cisplatin chemotherapy, will release its second quarter 2026 financial results on August 11, 2026, before U.S. market open. The company will host a conference call and webcast to discuss results. Fennec commercializes PEDMARK®,…

FENC

Aug 5, 2026

Sofia Navarro

Press Releases

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020, its investigational gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy. This designation, along with prior Orphan Drug and Fast Track statuses, highlights promising interim clinical data from the ongoing Phase I/II HEROIC-PKP2…

LXEO

Aug 5, 2026

Derek Hwang

Press Releases

Advantage Solutions Reports Second Quarter 2026 Results

Advantage Solutions Inc. reported Q2 2026 revenues of $889.5 million, a 1.8% increase year-over-year, driven primarily by growth in Experiential Services and slight growth in Retailer Services while Branded Services declined. Despite higher revenue, net loss widened to $62.7 million and Adjusted EBITDA dropped 12.2% to $75.8 million. The company re…

ADV

Aug 5, 2026

Maya Rios

Press Releases

TeraWulf Reports Second Quarter 2026 Results

TeraWulf reported second quarter 2026 results highlighting revenue growth with 102 MW of revenue-generating capacity at Lake Mariner and 336 MW under construction. The company secured a landmark 20-year, approximately $19 billion lease with Anthropic at its Kentucky Justified Data Campus and acquired the gigawatt-scale Muskie Data Campus. TeraWulf …

WULF

Aug 5, 2026

Hana Yamamoto

Press Releases

Astec Reports Second Quarter 2026 Results

Astec Industries, Inc. reported its second quarter 2026 financial results with net sales rising 23.6% to $408.1 million and backlog increasing nearly 58%. Despite growth in Materials Solutions, delays in Infrastructure Solutions asphalt plant shipments caused a reduction in full-year adjusted EBITDA guidance from $170-$190 million to $160-$175 mill…

ASTE

Aug 5, 2026

Nina Shah

Press Releases

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Atea Pharmaceuticals, a late-stage biopharmaceutical company developing oral antivirals for serious viral diseases, announced its Q2 2026 financial results call scheduled for August 12, 2026. The company continues to progress its Phase 3 hepatitis C program and Phase 1 hepatitis E study, sharing updates with investors.

AVIR

Aug 5, 2026

Avery Klein

Press Releases

Telix to Host R&D Day in New York City on September 22, 2026

Telix Pharmaceuticals Limited will host an R&D Day event in New York City on September 22, 2026, providing investors and analysts with a comprehensive update on its therapeutic and precision medicine pipeline. The event will feature presentations from company leadership and key opinion leaders, highlighting clinical, scientific, and strategic devel…

TLX

Aug 5, 2026

Nina Shah

Press Releases

Hennessy Capital Investment Corp. VII and ONE Nuclear Energy LLC Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination

Hennessy Capital Investment Corp. VII (NASDAQ: HVII) and ONE Nuclear Energy LLC announced that the SEC has declared effective their registration statement, enabling a shareholder meeting on August 24, 2026, to approve their proposed business combination. Upon closing, ONE Nuclear Energy Inc. will become a publicly traded company on NASDAQ under the…

ONEN

Aug 5, 2026

Nina Shah

Press Releases

J & J Snack Foods Reports Fiscal 2026 Third Quarter Results

J & J Snack Foods Corp. reported its fiscal 2026 third quarter results with a 6.2% decline in net sales to $426 million, impacted mainly by reduced bakery and frozen beverage machine sales. Despite lower sales, gross profit rose slightly and gross margin expanded by 240 basis points to 35.5%, attributed to operational efficiencies under the Apollo …

JJSF

Aug 5, 2026

Nina Shah

Press Releases

Royalty Pharma reports second quarter 2026 results

Royalty Pharma plc announced robust second quarter 2026 results with 14% growth in Royalty Receipts to $768 million and an overall 6% increase in Portfolio Receipts to $773 million. The company raised its full-year 2026 portfolio receipts guidance to $3.4 to $3.5 billion driven by strong performance of key products and active investments in new roy…

RPRX

Aug 5, 2026

Sofia Navarro

Press Releases

Kaltura Announces Financial Results for Second Quarter 2026

Kaltura, Inc. announced strong second quarter 2026 results, surpassing revenue and adjusted EBITDA guidance. Subscription revenue grew 8% year-over-year to $45.6 million, with total revenue at $46.9 million. The company achieved record non-GAAP gross margin of 75% and its highest Q2 adjusted EBITDA to date at $5.9 million. Kaltura signed a record f…

KLTR

Aug 5, 2026

Caleb Monroe

Press Releases

Climb Signs Distribution Agreement with Harmonic Security to Help Secure Mid-Market & Enterprise AI Adoption

Climb Global Solutions, Inc., a U.S.-based technology distributor, announced a distribution partnership with Harmonic Security to offer its AI governance platform to value-added resellers and managed service providers. This collaboration targets enhanced security for mid-market and enterprise adoption of AI, addressing risks from autonomous AI agen…

CLMB

Aug 5, 2026

Ajmal Hussain

Press Releases

VisionWave Expands AI Defense Platform with Planned Acquisition of Perimeter Security Provider D-Fence

VisionWave Holdings, Inc. announced a planned acquisition of at least 51% of D-Fence Electronic Fencing Systems Ltd., an Israeli developer of AI-driven perimeter security technologies used in critical infrastructure worldwide. The transaction aims to build a comprehensive AI-powered defense platform by integrating D-Fence's solutions with VisionWav…

VWAV

Aug 5, 2026

Priya Menon

Press Releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma reported positive regulatory milestones, including a favorable CHMP opinion recommending marketing authorization for obicetrapib and its fixed-dose combination with ezetimibe in Europe. The company provided updates on ongoing Phase 3 cardiovascular and Alzheimer's disease trials, announced cash position of $678.3 million as of J…

NAMS

Aug 5, 2026

Ajmal Hussain

Press Releases

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported robust Q2 2026 financial results with total net revenue of $218.3 million, an operating profit of $98.5 million, and maintained full-year ORLADEYO revenue guidance while raising total revenue outlook. Key milestones include starting shipments of ORLADEYO oral pellets for pediatric hereditary angioedema patients and…

BCRX

Aug 5, 2026

Maya Rios

Press Releases

Ascent Solar Technologies Meets Growing Drone Market Demand; Reinforces Primary Space Industry Focus

Ascent Solar Technologies highlights its growing involvement in the expanding drone market alongside its core space industry applications. The company secured orders from satellite manufacturers and unmanned aerial and marine vehicle producers, showcasing its innovative thin-film photovoltaic technology that offers a superior power-to-weight ratio.…

ASTI

Aug 5, 2026

Nina Shah

Press Releases

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics reported Q2 2026 financial results highlighting rapid enrollment completion of their KT-621 Phase 2b trial in atopic dermatitis ahead of schedule, with topline data expected by year-end 2026. The company plans to initiate Phase 3 trials in mid-2027 and reported ongoing progress in multiple clinical programs addressing immunologi…

KYMR